
Ophthalmology
Latest News
Latest Videos

Podcasts
CME Content
More News

Review top news and interview highlights from the week ending September 26, 2025.

SAR446268 has previously received orphan drug designations from the FDA and European Medicines Agency.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Part B of LIGHTHOUSE enrolled 9 patients and is expected to enroll 3 pediatric patients.

Review top news and interview highlights from the week ending September 19, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

SAR402663 comprises a onetime intravitreal treatment and is intended to inhibit VEGF by providing a gene for soluble FLT01.

In episode 6 of ImmunoLogic, Stephen Schoenberger, PhD, discussed his research on customized cancer vaccines.

Review top news and interview highlights from the week ending September 12, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending September 5, 2025.

Notably, the European Medicines Agency also granted MCO-010 orphan drug designation for 5 retinal dystrophy categories.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Review top news and interview highlights from the week ending August 29, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending August 22, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending August 15, 2025.

Notably, the first patient was dosed in the GARDian3 in July 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

AAVB-039 is intended to deliver a functional copy of the disease-targeted ABCA4 gene.

Review top news and interview highlights from the week ending August 8, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.




























